dc.contributor.author | Pan American Health Organization | |
dc.date.accessioned | 2020-07-01T21:00:08Z | |
dc.date.available | 2020-07-01T21:00:08Z | |
dc.date.issued | 2020-04-06 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/1910 | |
dc.identifier.uri | https://iris.paho.org/handle/10665.2/52094 | |
dc.description.abstract | In recent weeks, information on the potential use of chloroquine or hydroxychloroquine for the treatment of people with COVID-19 has been disseminated in academic journals and public media. Although there are now ongoing clinical trials testing the efficacy and safety of several medicines for COVID-19, as of the date of this document, there is a lack of quality evidence to demonstrate chloroquine and/or hydroxychloroquine are effective in the treatment of COVID-19. Evidence is recently emerging via small studies with sub-optimal methodologies that are conflicting.
In some countries in the Americas, chloroquine or hydroxychloroquine is readily available, in some cases as an over-the-counter medicine. National authorities should take measures to control the use of these medicines and prevent self-medication. The use of chloroquine and/or hydroxychloroquine outside of current guidelines and recommendations may result in adverse effects, including serious illness and death, and have a negative impact on other diseases where there is proven benefit. Public health authorities are urged to prioritize resources on those interventions that are currently recommended for standard of care. | |
dc.language | English | |
dc.subject | Infecctious Diseases | |
dc.subject | COVID-19 | |
dc.subject | Coronavirus | |
dc.title | COVID-19: Chloroquine and hydroxychloroquine research, 6 April 2020 | |
eihealth.country | Regional, Americas (PAHO/OPS) | |
eihealth.category | Infection prevention and control, including health care workers protection | |
eihealth.type | WHO/PAHO Guidance | |
eihealth.maincategory | Slow Spread / Reducir la Dispersi�n | |